Cefepime and mortality in pediatric acute myelogenous leukemia: a retrospective cohort study.

摘要: Background: Based on 2 meta-analyses, the Food and Drug Administration issued a communication in 2009 regarding potential risk of death patients treated with cefepime. Pediatric acute myelogenous leukemia (AML) have frequent episodes fever necessitating use antibiotics such as We evaluated association cefepime other beta-lactam antibiotic exposures all cause in-hospital mortality pediatric AML patients. Methods: performed retrospective cohort study using Health Information System, an inpatient database. Exposure to cefepime, ceftazidime, antipseudomonal penicillin, carbapenems was for each 30-day period within first year from diagnosis. Cox regression analysis used compute hazard ratios (HR) adjusting demographics, clinical variables, clustering by hospital. The final distinct time periods (0-3 months >3-12 months) account variation proportional hazards over time. Results: No differences between HRs were observed 0 3 (cefepime vs. ceftazadime: HR = 1.33, 95% CI: 0.70-2.52; antipseudmonal penicillin: 0.86, 0.34-2.13; carbapenems: 1.08, 0.50-2.35) or >3 12 after diagnosis 1.29, 0.53-3.15; HR=1.08, 0.44-2.66; 1.03, 0.45-2.33). Conclusions: In this patients, exposure 30 days preceding did not result increased when compared penicillins, carbapenems.